Table 2.

Comparison of our results with the case series from Clotman et al and Stamatouli et al.^43,62

Parameter	Current study (n=72)	Clotman study (n=41)	Stamatouli study (n=27)
Median age, years (IQR)	63 (22–83)	63 (28–83)	66 (49–87)
Gender, % (male:female)	52.8:47.2	51.2:48.8	62.9:37.1
Index presentation with DKA or ketosis, %	77.8	71.4	59.0
Diabetes-related autoantibodies, %	44.4	56.0	40.0
GAD positivity, %	39.4	56.0	NCD
HbA1c, mmol/mol (IQR)	53 (39.9–101.1)	53 (46.4–93.4)	63.4 (42.1–90.2)
Proportion of cases with reduced C-peptide <1.1 ng/mL, %	62.5	93.0	85.0
HLA genotypes, %	NCD	NCD	HLA-DR4: 76 HLA-DR3: 34.1 HLA-DQ8 (DQB1*0302): 38.0
Proportion of patients in whom ICI therapy continued after diagnosing diabetes, %	41.7	NCD	37.0
Proportion of patients treated with insulin for ICI-induced diabetes, %	98.6	NCD	NCD

DKA = diabetes-related ketoacidosis; GAD = glutamic acid decarboxylase; HbA1c = glycated haemoglobin; HLA = human leukocyte antigen; ICI = immune checkpoint inhibitor; IQR = interquartile range; NCD = not clearly documented.